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Sir, 
We are grateful to Guillermo Ruiz-Irastorza and colleagues for their very positive comments 
(1) about the British Society for Rheumatology guideline for the management of systemic 
lupus erythematosus in adults(2).  Regarding their comments suggesting that we might have 
been more radical regarding the dose and duration of corticosteroids we would like to 
emphasise that we did state in the main text of the executive summary(3) and in the full 
guideline(2), as well as in our table in both documents suggesting dosing regimens for active 
disease and maintenance therapy, that the lowest effective dose should be used at all times.  
 
We are well aware of the toxicity of high dose corticosteroids and that many patients will 
respond to doses well below 1mg/kg/day for severe flares. However there is considerable 
variation in dosing required in different patients with various lupus manifestations, 
particularly if they are already on corticosteroids. If intravenous pulses are not being used for 
any reason, oral doses of prednisolone or equivalent in the range of up to 0.75-1 mg/kg/day 
may be required for life-threatening conditions unresponsive to the lower dose such as up to 
0.5mg/kg/day as suggested first in the table. We specifically recommend in the main 
guideline section on severe lupus therapy with corticosteroids(2) that the lower dose oral and 
intravenous regimens should be used rather than the higher doses that have been used in the 
past. We never suggested that prednisolone doses greater than 30mg/day were required for 
any specific indication. 
 
We did not quote the paper by Ruiz-Arruza et al.(4) as it was published in early June 2015, 
just after we ran our last literature search for corticosteroids and we can only apologise that 
we did not pick this up later and for any other omissions. However this paper and other 
reports of corticosteroid regimens used in lupus nephritis mentioned by Ruiz-Irastorza et 
al.(1) do not address or exclude the need for patients with very severe lung, cardiac, gastro-
intestinal, haematological and neuro-psychiatric lupus requiring higher dose corticosteroid 
regimens, particularly as the entry criteria for the study reported by Riuz-Arruza et al.(4) was 
a SLEDAI score of only 6 or more. 
 
We did not provide any specific recommendations for tapering corticosteroids in non-renal 
lupus as there was little evidence for a reliable strategy for all lupus patients when we defined 
the topics for our literature review. This is certainly a topic worthy of further discussion in 
the light of new evidence in a future revision of the guideline and we did emphasise reduction 
to a safer target dose of <7.5 mg/kg/day to avoid complications of corticosteroid therapy so 
we would not expect patients to be exposed to high doses for long periods of time. In the 
section on key standards of care at the end of the main guideline we discuss again the 
importance of using the least amount of corticosteroids possible and the importance of 
adjusting therapy if treatment is not producing the desired effect within the expected time 
frame to reduce the risk of accumulation of chronic damage. 
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